Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07287137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Study acronym: CIRV2
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 8 words
    • Study description revised
    v3
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Trial Details
NCT Number NCT07287137
Lead Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: Centers for Disease Control and Prevention, Food and Drug Administration (FDA)
Conditions
(from sponsor)		 COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Related terms COVID-19, Influenza, Human
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov